Medpace (NASDAQ:MEDP) Surpasses Estimates with 32% Q4 Revenue Growth

Medpace Holdings (NASDAQ:MEDP) reported Q4 CY2025 revenue of $708.5 million, up 32% year-on-year, and GAAP EPS of $4.67, 11.4% above estimates. The company guided to full-year revenue of $2.81 billion and EPS of $15.30 for CY2025, in line with analyst expectations. Supporting context: Organic revenue growth averaged 15.9% over the last two years, reflecting core operational strength. The company’s operating margin expanded 3.8 percentage points over five years to 21.6% in Q4 despite a modest 1.7 percentage point decline YoY. EPS growth over the same period was 31.7% CAGR, outpacing revenue expansion. Share count declined 23.1% during the period, enhancing EPS. Publication: February 9, 2026.